Regenxbio (RGNX) Current Deferred Revenue (2014 - 2025)
Regenxbio's (RGNX) quarterly Current Deferred Revenue came in at $29.4 million in Q4 2025, up 25465.22% year-on-year from N/an in Q4 2024, and up 122.81% quarter-over-quarter from $13.2 million in Q3 2025.
Regenxbio (RGNX) Current Deferred Revenue (2014 - 2025) Analysis & Trends
Regenxbio's Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $29.4 million for Q4 2025.
- On a quarterly basis, Current Deferred Revenue rose 25465.22% year-over-year to $29.4 million in Q4 2025; TTM through Dec 2025 was $29.4 million, a 25465.22% increase from a year earlier, with the FY2025 full-year figure at $29.4 million, up 25465.22% from the prior year.
- Current Deferred Revenue advanced to $29.4 million in Q4 2025 per RGNX's latest filing, from $13.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $39.9 million in Q1 2025 and bottomed at $13000.0 in Q1 2024.
- The 5-year median for Current Deferred Revenue is $3.3 million (2021), against an average of $7.8 million.
- Across the five-year window, Current Deferred Revenue tumbled 99.01% in 2024 and jumped 306707.69% in 2025, its largest moves.
- Year by year, Current Deferred Revenue stood at $3.3 million in 2021, then tumbled by 45.12% to $1.8 million in 2022, then slumped by 91.91% to $148000.0 in 2023, then declined by 22.3% to $115000.0 in 2024, then surged by 25465.22% to $29.4 million in 2025.
- Per Business Quant, the three latest RGNX Current Deferred Revenue figures stand at $29.4 million (Q4 2025), $13.2 million (Q3 2025), and $37.8 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Regenxbio | 528.62 Mn | 298.55 Mn | 21.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29.40 Mn |
| Sep 30, 2025 | 13.20 Mn |
| Jun 30, 2025 | 37.78 Mn |
| Mar 31, 2025 | 39.89 Mn |
| Dec 31, 2024 | 115,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Sep 30, 2023 | 442,000.00 |
| Jun 30, 2023 | 448,000.00 |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 5.90 Mn |
| Jun 30, 2022 | 6.64 Mn |
| Mar 31, 2022 | 3.33 Mn |
| Dec 31, 2021 | 3.33 Mn |
| Sep 30, 2021 | 3.93 Mn |
| Jun 30, 2021 | 4.03 Mn |
| Mar 31, 2021 | 4.12 Mn |